US OptionsDetailed Quotes
VTYX241220P2500
- 0.12
- 0.000.00%
15min DelayClose Dec 2 16:00 ET
0.00High0.00Low
0.12Open0.12Pre Close0 Volume409 Open Interest2.50Strike Price0.00Turnover73.77%IV5.56%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type-0.4436Delta0.9677Gamma16.80Leverage Ratio-0.0045Theta-0.0006Rho-7.45Eff Leverage0.0022Vega
Ventyx Biosciences Stock Discussion
Sign in to post a comment
Columns Pay me
Here have some gifts, my weekend work so far:
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...
4
1
$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...
$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price...
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price...
$Ventyx Biosciences (VTYX.US)$ Reuters· just
Ventyx Biosciences Announces $27 Million Strategic Investment From Sanofi
Ventyx Biosciences Announces $27 Million Strategic Investment From Sanofi
1
$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a str...
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a str...
1
$Ventyx Biosciences (VTYX.US)$ Reuters· just
Ventyx Biosciences Inc - Vtx958 Phase 2 Trial Fails Primary Endpoint in Crohn's Disease
Ventyx Biosciences Inc - Vtx958 Phase 2 Trial Fails Primary Endpoint in Crohn's Disease
3
No comment yet
Tonyco OP : (all of them tank 30%, is murdered under mysterious circumstances days later)